Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy

详细信息    查看全文

• 作者：Yushi Ueki ; Yuichiro Tada ; Takafumi Togashi…
• 刊名：International Cancer Conference Journal
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：5
• 期：3
• 页码：150-153
• 全文大小：1,195 KB
• 刊物主题：Oncology; Surgical Oncology;
• 出版者：Springer Japan
• ISSN：2192-3183
• 卷排序：5

文摘

Salivary duct carcinoma (SDC) has a poor prognosis owing to the high incidence of distant metastasis. Approximately 40 % of SDCs are positive for human epidermal growth factor receptor 2 (HER2), suggesting that anti-HER2 therapy for cases with distant metastasis may be effective. However, the pathological response of SDC metastases to anti-HER2 therapy has not been reported. A 44-year-old man was diagnosed with HER2-positive SDC of the submandibular gland with multiple distant metastases. After six cycles of trastuzumab/docetaxel therapy, the patient achieved clinical partial response for the primary tumor and complete response for the neck and distant metastases. Subsequently, the patient underwent submandibular gland resection and neck dissection. On histopathological examination, very few viable cancer cells were identified in the resected primary tumor. Unfortunately, the patient died of multiple distant metastases 12 months after initial treatment. Trastuzumab/docetaxel therapy can elicit a clinical and pathological response in HER2-positive SDC.KeywordsSalivary duct carcinomaHER2TrastuzumabDocetaxelMetastases